



**Dr. Albert Bourla**  
Chairman of the Board  
Chief Executive Officer

Pfizer Inc  
[Redacted]  
[Redacted]  
[Redacted]@pfizer.com

March 16, 2020

**Mrs. Ursula von der Leyen**  
**President**  
European Commission  
Rue de la Loi 200  
B-1049 Brussels

Dear President von der Leyen,

First of all, thank you for your leadership during this global health crisis. For that, myself and all of my colleagues at Pfizer are extremely grateful. We appreciate the Commission's announcement on March 13 setting out a coordinated European response to the public health emergency resulting from the COVID-19 pandemic.

I wanted to update you on Pfizer's efforts to contribute to the world's crusade to overcome this crisis.

First, like many other responsible corporate citizens, Pfizer is taking all necessary measures to protect the health and well-being of our employees while minimizing the impact on our operations. We are paying close attention to the potential for delays in our research programs and ongoing clinical trials that could result in a lag in bringing life-saving medicines and vaccines to patients and we are doing everything in our power to minimize this impact. In addition to this broader response we are focusing on two areas where we can specifically help to combat this disease: (1) maintaining the supply of critical hospital medications that are needed to treat COVID-19 patients, and (2) developing a medical solution to combat this disease.

#### **Maintaining supply of critical hospital medications**

Pfizer has a world leading sterile injectables portfolio. Every year we supply more than 1.5 billion units in tens of thousands of healthcare institutions around the world. As of today all our manufacturing sites are running at high capacity under a Pfizer wide pandemic preparedness plan. In order to maintain our capacity we have moved all sites to phase two of this plan which restricts access to only those colleagues critical for sustained operations. We will keep monitoring the situation in case additional measures are required.

In addition, we have identified 74 medicines used globally that are most relevant in today's situation for hospitals and affected patients (47 in the anti-infective space and 27 that are core to institutions providing patients supportive and critical care). We are developing specific risk plans for these medicines that include but are not limited to intensive monitoring of demand and shifting production plans to support higher demand and safety stocks.

#### **Develop medical solutions against CoVid-19**

Pfizer has also created a SWAT team of our leading virologists, biologists, chemists, clinicians, epidemiologists, vaccine experts, pharmaceutical scientists and other key experts to focus solely on addressing this pandemic and we are in the race to develop antiviral therapies and a coronavirus vaccine. Although it is still very early, we see a significant opportunity to contribute to public health with an antiviral treatment in the clinic before end of 2020 and a vaccine in the US for testing within a few months. However, in order to find a solution as soon as possible, it is



critical there be collaboration between the biopharmaceutical industry and government moving forward. In that spirit, Pfizer yesterday issued a Five Point Plan of commitments in this regard. Pfizer is making five promises that will help scientists more rapidly bring forward therapies and vaccines to protect humankind from this escalating pandemic and prepare the industry to better respond to future global health crises.

The Pfizer Five Point Plan is as follows:

- 1. Sharing tools and insights:** With very little known about this virus, many are working to develop cell-based assays, viral screening, serological assays, and translational models to test potential therapies and vaccines. Pfizer is committed to making the vital tools we develop available on an open source platform to the broader scientific community and to sharing the data and learnings gained with other companies in real time to rapidly advance therapies and vaccines to patients.
- 2. Marshalling our people:** Human capital is our most valuable resource. Pfizer has created a SWAT team of our leading virologists, biologists, chemists, clinicians, epidemiologists, vaccine experts, pharmaceutical scientists and other key experts to focus solely on addressing this pandemic. This team is applying their passion, commitment and expertise to a single focus of accelerating the discovery and development process that will deliver therapies and vaccines to patients as soon as possible.
- 3. Applying our drug development expertise:** Many smaller biotech companies are screening compounds or existing therapies for activity against the virus causing COVID-19, but some lack the experience in late stage development and navigating the complex regulatory systems. Pfizer is committed to sharing our clinical development and regulatory expertise to support the most promising candidates these companies bring forward.
- 4. Offering our manufacturing capabilities:** Once a therapy or vaccine is approved it will need to be rapidly scaled and deployed around the world to put an end to this pandemic. As one of the largest manufacturers of vaccines and therapeutics, Pfizer is committed to using any excess manufacturing capacity and to potentially shifting production to support others in rapidly getting these life-saving breakthroughs into the hands of patients as quickly as possible.
- 5. Improving future rapid response:** Finally, to address future global health threats, Pfizer is reaching out to US federal agencies including NIH, NIAID and CDC to build a cross-industry rapid response team of scientists, clinicians and technicians able to move into action immediately when future epidemics surface.

Please let me know how I may be of further assistance to you and your team. And again, thank you for your commitment and partnership to tackle this crisis.

Sincerely,



Dr. Albert Bourla  
Chairman of the Board  
Chief Executive Officer

Cc: Mrs. Stella Kyriakides, Commissioner for Health and Food  
Mr. Bjoern Seibert, Head of Cabinet for President van der Leyen  
Mr. Giorgos Rossides, Head of Cabinet for Commissioner Kyriakides